Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.78 |
| ▸ | ITK | Q08881 | 2/20 | 0.70 |
| ▸ | FGR | P09769 | 1/20 | 0.70 |
| ▸ | FLT3 | P36888 | 1/20 | 0.70 |
| ▸ | CSK | P41240 | 1/20 | 0.70 |
| ▸ | BLK | P51451 | 1/20 | 0.70 |
| ▸ | JAK3 | P52333 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 2/20 | 0.68 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.63 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.62 |
| ▸ | LYN | P07948 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20144255 | 0.91 | BTK (0.91) | BTKITKFGRFLT3CSK | |
| SCHEMBL22777861 | 0.90 | BTK (0.82) | BTKITKFGRFLT3CSK | |
| SCHEMBL20144263 | 0.89 | BTK (0.91) | BTKITKFGRFLT3CSK | |
| SCHEMBL20144254 | 0.89 | BTK (0.80) | BTKITKFGRFLT3CSK | |
| SCHEMBL24197246 | 0.89 | BTK (0.71) | BTKITKFGRFLT3CSK | |
| SCHEMBL25468776 | 0.88 | BTK (0.81) | BTKITKFGRFLT3CSK | |
| SCHEMBL21330628 | 0.88 | BTK (1.00) | BTKITKFGRFLT3CSK | |
| SCHEMBL20177256 | 0.88 | BTK (1.00) | BTKITKFGRFLT3CSK | |
| SCHEMBL22720866 | 0.87 | BTK (0.77) | BTKITKFGRFLT3CSK | |
| SCHEMBL22721085 | 0.87 | BTK (0.77) | BTKITKFGRFLT3CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| EP-4180432-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | BTK 1/4885ITK 4/4885FGR 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.